GILD - Starpharma Viraleze: COVID-19 Nasal Spray Development

• Viraleze antiviral could be effective against SAS-CoV-2 and RSV. Boston Consulting Group is involved in positioning and marketing this preventative/early stage infection product.
• Viraleze has a fast-track to market in Europe based on antiviral activity, not efficacy of preventing COVID-19 infection. Therefore, minimal regulatory needs in Europe.
• Viraleze is positioned as a preventative and also “morning after” exposure treatment, which is stable at room temperature and, therefore, compatible with handbag or briefcase use.
• Starpharma’s DEP-remdesivir overcomes some disadvantages of remdesivir; it is having undisclosed discussions with Gilead.
• Plan to license internal DEP oncology products at end of Phase 2, with 2 or 3 oncology products completing Phase 2 by mid-next year? Several events in 2021 that could substantially positively impact the share price.

For further details see: